On the other hand, SP2 (Supplementary Figure 8A), ZBTB33 (Supplementary Figure 8B), ZNF91_extended (Supplementary Figure 8C), SOX4 (Supplementary Figure 8D), and SOX9 (Supplementary Figure 8E) are marked as biomarkers of low FeAS GBM cells, and higher enrichment of pathways like DNA replication, ubiquitination modification is identified. This evidence concerns the gene SP2 and glioblastoma.